SCHEMBL3493700

SCHEMBL3493700

COc1ccc2c(c1)C(=O)CC1(CCN(C(=O)c3c(N)sc4nc(C)ccc34)CC1)S2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 3/20 0.40
KDM4E B2RXH2 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
CES2 O00748 1/20 0.36
RYR2 Q92736 2/20 0.34
IKBKB O14920 1/20 0.34
LIMK1 P53667 1/20 0.34
ACACB O00763 4/20 0.34
ACACA Q13085 4/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636854 0.91 ACACB (0.35) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3490756 0.91 NPC1 (0.35) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3492698 0.89 ACACB (0.34) ALDH1A1HSD17B10KDM4ESMN1; SMN2TP53
SCHEMBL3494981 0.89 ACACB (0.35) ALDH1A1SMN1; SMN2TP53MAPTIKBKB
SCHEMBL3494892 0.89 ACACB (0.40) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3494893 0.89 ACACB (0.40) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3492562 0.87 MAPT (0.36) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3494572 0.87 SMN1; SMN2 (0.33) ALDH1A1KDM4ESMN1; SMN2MAPTALOX15
SCHEMBL13367513 0.85 NPC1 (0.35) ALDH1A1HPGDHSD17B10KDM4ERAB9A
SCHEMBL3494006 0.84 ACACB (0.35) ALDH1A1TP53MAPTIKBKBLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113418-A1 HETEROCYCLIC COMPOUND ACACA, ACAT1, CPT1B ALDH1A1 503/4885HPGD 1103/4885HSD17B10 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.